Literature DB >> 35875321

Neurological and neuropsychological sequelae of Zika virus infection in children in León, Nicaragua.

Jill F Lebov1, Stephen R Hooper2, Norma Pugh1, Sylvia Becker-Dreps2, Natalie M Bowman2, Linda M Brown1, Pia D M MacDonald1, Premkumar Lakshmanane2, Ramesh Jadi2, Filemon Bucardo3, Tatiana Chevez3, Andrés Herrera Rodriguez3, Teresa de Jesús Aleman Rivera3.   

Abstract

Objectives: To describe the presence and persistence of neurological and neuropsychological sequelae among children with acquired Zika virus infection and assess whether those sequelae were more common in children infected with Zika virus compared to uninfected children.
Methods: We conducted a prospective cohort study of children with and without Zika virus infection in León, Nicaragua, using a standard clinical assessment tool and questionnaire to collect data on symptoms at three visits, about 6 months apart, and a battery of standardized instruments to evaluate neurocognitive function, behavior, depression, and anxiety at the last two visits.
Results: Sixty-two children were enrolled, with no significant differences in demographics by infection group. Children infected with Zika virus had a range of neurological symptoms, some of which persisted for 6 to 12 months; however, no consistent pattern of symptoms was observed. At baseline a small percentage of children infected with Zika virus had an abnormal finger-to-nose test (13%), cold touch response (13%), and vibration response (15%) versus 0% in the uninfected group. Neurocognitive deficits and behavioral problems were common in both groups, with no significant differences between the groups. Children infected with Zika virus had lower cognitive efficiency scores at the 6-month visit. Anxiety and depression were infrequent in both groups. Conclusions: Larger studies are needed to definitively investigate the relationship between Zika virus infection and neurological symptoms and neurocognitive problems, with adjustment for factors affecting cognition and behavior, including mood and sleep disorders, home learning environment, history of neuroinvasive infections, and detailed family history of neuropsychological problems.

Entities:  

Keywords:  Nicaragua; Zika virus infection; child; nervous system diseases; neuropsychological tests

Year:  2022        PMID: 35875321      PMCID: PMC9299389          DOI: 10.26633/RPSP.2022.90

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


Zika virus (ZIKV) is a mosquito-borne flavivirus that infected millions of people in the Americas and across the globe in 2015 and 2016 (1). Although ZIKV infection typically presents with mild symptoms, the World Health Organization declared ZIKV infection a Public Health Emergency of International Concern because of its apparent association with severe central nervous system anomalies in fetuses and neonates with congenital exposure to ZIKV (2, 3). Although studies have evaluated the biological pathways and outcomes of congenital ZIKV infection, research into postnatally acquired ZIKV infection in children is limited (4, 5). While symptomatic ZIKV infection in postnatally exposed children appears to be mild (6), severe neurological complications have been described in case reports (7), epidemiological studies (8–10), and in postnatally exposed animals (11, 12). However, information about neurological complications is limited. The only study to date to evaluate neurocognitive functioning among children with acquired ZIKV infection assessed 37 people infected with ZIKV, aged 12 years and older, and found that they had lower memory scores compared to a dengue-infected group (13). Like many Latin American countries, Nicaragua experienced epidemic spread of ZIKV throughout the country during 2016 (13, 14). To better understand the potential impacts of ZIKV infection, we conducted a prospective cohort study of neurological symptoms and neuropsychological functioning in ZIKV-infected children and uninfected children in León, Nicaragua.

METHODS

Study population

Nicaragua, a Central American nation with a population of 6.1 million in 2016, is among the lowest-income countries in Latin America (14). The department of León is an economically and geographically diverse region with a high intensity of Aedes aegypti mosquito-transmitted arboviruses. Between January 2016 and August 2017, researchers at the University of North Carolina, Chapel Hill and the Universidad Nacional Autónoma de Nicaragua, León conducted a ZIKV transmission study that included patients aged 2 years and older seeking care at the Perla Maria de Nori Health Center for fever, maculopapular rash, or non-suppurative conjunctivitis of less than 1 week’s duration and asymptomatic household members (15). Thirty-five per cent of those enrolled in the study were children. Between November 2016 and March 2018, children aged 2–17 years from the transmission study were recruited to participate in a study of neurological symptoms and neuropsychological functioning. Eligibility criteria included: complete data on age, sex, and ZIKV status; and parental permission/assent to participate in three study visits, conducted about 6 months apart.

Definition of Zika-infected and uninfected children

Convalescent serum specimens collected from participants at the second and third visits were stored temporarily in the laboratory of the Universidad Nacional Autónoma de Nicaragua, León before shipment to the University of North Carolina for testing. ZIKV infection was defined as a positive result in one or both specimens using a modified version of a validated serological assay based on Z-EDIII antigen (16). The assay has been validated with a larger panel of samples shown to be highly specific for ZIKV infection in convalescent samples collected after 2 months. Based on well characterized samples, an optical density cut-off of 0.34 was used to indicate prior ZIKV infection. Participants without convalescent specimens were tested in the transmission study by a reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) test using a Roche LightCycler 96 at the Universidad Nacional Autónoma de Nicaragua, León laboratory, using previously described methods (15, 17). Participants with positive PCR results were also included in the ZIKV-infected group. Participants with a negative RT-qPCR but no serology were excluded due to uncertainty about their ZIKV status; all other participants were characterized as Zika-uninfected.

Study assessments

A study physician was trained by a neurology professor from University of North Carolina-Chapel Hill to conduct the neurological examination. At each visit, the physician conducted a clinical assessment of a standard set of neurological signs and symptoms and administered a questionnaire to the participant or the participant’s parent/guardian about recent changes in function that could be associated with neurological deficits. The clinical assessment included evaluation of: awareness level; general speech/language; visual acuity; ocular movement; facial and upper and lower extremity strength; bicep, knee, and ankle reflexes; a finger-to-nose test; cold and vibration touch response; and gait. The questionnaire assessed: current energy level (fatigue); interest in social activities; experience of memory loss or confusion; problems with speed of thought or concentration; headache or seizure in the previous 4 weeks; recent problems with hearing, vision, walking, use of hands and arms, bladder control, or numbness, tingling, or loss of feeling in any part of the body. For any indicated abnormality, additional questions sought information about the severity of the problem and timing (i.e., started 1 week, 2 weeks, 1 month, 1–6 months, or more than 6 months before). At the second and third visits, about 6 and 12 months, respectively, after the baseline visit, a trained psychologist or physician conducted a battery of age-appropriate neuropsychological assessments – Woodcock Muñoz III Cognitive Battery (18, 19), Test of Nonverbal Intelligence 4 (20), the Child Behavior Checklist (21), and depression and anxiety questionnaires as appropriate for age group, i.e., Children’s Depression Inventory (22), Beck Depression Inventory (23), Spence Child Anxiety Scale (24), and Beck Anxiety Scale (25). For the Woodcock Muñoz III Cognitive Battery, raw scores from all reported subtests and composite variables were converted to age-based standard scores. Two composite scores are reported: cognitive efficiency (visual matching and numbers reversed) and working memory (numbers reversed and auditory working memory). Overall raw scores of the Test of Nonverbal Intelligence 4 were converted to age-based standard scores. The standard score scale for the Woodcock Muñoz III Cognitive Battery and Test of Nonverbal Intelligence 4 is based on a mean of 100 and standard deviation (SD) of 15. For the Child Behavior Checklist, raw scores for all reported items and composite domains were converted to age-based t-scores. The standard score scale is based on a mean of 50 and SD of 10. The t-tests of parent response score distributions across age group (2–5 years and 6–18 years) indicated that compilation of form data into a single dataset was appropriate. For all other instruments, we examined the total summed score. Children are considered at risk for diagnosable cognitive, behavioral, and/or mood disorders if their score falls above or below a certain threshold. Additional details about these instruments, including the definition of at-risk scores, are outlined in Table 1. To ensure that terminology was locally appropriate to the Nicaraguan context, we pilot tested all instruments among a small number of children and their parents.
TABLE 1.

Description of assessments included in the neuropsychological assessment battery

Assessment

Administration method (age range of administration)

Measured constructs and outcomes

At-risk score defined as:

Woodcock-Muñoz III Cognitive Battery

Direct assessment by evaluator (2–18 years)

Comprehension-knowledge, visual-spatial thinking, auditory processing, processing speed, short-term memory, long-term retrieval, working memory, broad attention, and executive processes.

≤ 1.5 SDs from the mean (i.e., a score of ≤ 78)

Test of Nonverbal Intelligence-4

Direct assessment by evaluator (6–18 years)

Assessment of intelligence, aptitude, abstract reasoning, and problem solving. Language-free, thus ideal for evaluating those with limited language ability.

≤ 1.5 SDs from the mean (i.e., a score of ≤ 78)

Child Behavior Checklist

Caregiver report (2–18 years)

Ratings of internalizing, externalizing, and total behavior problems, and specific clinical scales (e.g., attention problems, anxiety, and withdrawal) which vary depending on age group.

≥ 1.5 SDs from the mean (i.e., a score of ≥ 65)

Child Depression Inventory

Self-report (7–12 years)

Evaluates dysphoria (e.g., depressive mood, sadness, and worry) and negative self-esteem (e.g., inefficacy and wickedness).

≥ 19

Beck Depression Inventory

Self-report (13–18 years)

Intensity of depression.

≥ 31

Spence Child Anxiety

Questionnaire

Self-report (8–12 years)

Frequency of occurrence of experiences of anxiety, fears, and self-rating of positive aspects.

Ages 8–11 years, total scores ≥ 40 (males), ≥ 50 (females)

Ages 12–15 years, total scores ≥ 33 (males), ≥ 39 (females)

Beck Anxiety Scale

Self-report (13–18 years)

Subjective, somatic, or panic-related anxiety

≥ 36

SD, standard deviation.

Assessment Administration method (age range of administration) Measured constructs and outcomes At-risk score defined as: Woodcock-Muñoz III Cognitive Battery Direct assessment by evaluator (2–18 years) Comprehension-knowledge, visual-spatial thinking, auditory processing, processing speed, short-term memory, long-term retrieval, working memory, broad attention, and executive processes. ≤ 1.5 SDs from the mean (i.e., a score of ≤ 78) Test of Nonverbal Intelligence-4 Direct assessment by evaluator (6–18 years) Assessment of intelligence, aptitude, abstract reasoning, and problem solving. Language-free, thus ideal for evaluating those with limited language ability. ≤ 1.5 SDs from the mean (i.e., a score of ≤ 78) Child Behavior Checklist Caregiver report (2–18 years) Ratings of internalizing, externalizing, and total behavior problems, and specific clinical scales (e.g., attention problems, anxiety, and withdrawal) which vary depending on age group. ≥ 1.5 SDs from the mean (i.e., a score of ≥ 65) Child Depression Inventory Self-report (7–12 years) Evaluates dysphoria (e.g., depressive mood, sadness, and worry) and negative self-esteem (e.g., inefficacy and wickedness). ≥ 19 Beck Depression Inventory Self-report (13–18 years) Intensity of depression. ≥ 31 Spence Child Anxiety Questionnaire Self-report (8–12 years) Frequency of occurrence of experiences of anxiety, fears, and self-rating of positive aspects. Ages 8–11 years, total scores ≥ 40 (males), ≥ 50 (females) Ages 12–15 years, total scores ≥ 33 (males), ≥ 39 (females) Beck Anxiety Scale Self-report (13–18 years) Subjective, somatic, or panic-related anxiety ≥ 36 SD, standard deviation.

Statistical analyses

We calculated descriptive summary statistics overall and by ZIKV infection for baseline characteristics of interest and performed chi-squared tests to determine if there were any differences between groups. To investigate the long-term sequelae in children with ZIKV infection, we describe self-reported and physician-observed neurological symptoms and neuropsychiatric deficits in children who had their baseline visit within 60 days of enrollment into the transmission study. Because all participants were asked to provide information about the estimated timing of the start of neurological symptoms, we compared that to the timing of infection to determine whether the reported problem began after or before ZIKV infection, or whether the timing was unknown. Only post-infection symptoms are reported for the baseline, 6-month, and 12-month visits in this descriptive analysis. Finally, we examined neuropsychological functioning at the 6- and 12-month visits by ZIKV infection. For each test and select subtests, we generated descriptive summary statistics and the prevalence of children at risk. We calculated difference in prevalence at risk between the infected and uninfected groups, including 95% confidence intervals (CIs), using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Ethics statement

The Institutional Review Board of RTI International reviewed and approved this study. Study staff read consent forms to parents or guardians accompanying minors who participated in this study, and read assent forms to minors aged 7–17 years. Parents/guardians and minors aged 7–17 years had the opportunity to ask questions about the study before signing the consent and assent forms or declining to participate. Copies of the consent and assent forms were provided to participants. Parents or guardians of participating minors were provided with a monetary reimbursement to cover their time and transportation. All participant information was kept confidential by securing paper records locked in the study coordinator’s office and entering data into a password-protected web-based REDCap electronic database hosted by RTI International (26).

RESULTS

Sample characteristics

Of 77 children enrolled in the transmission study at the time of suspected ZIKV infection, 71 consented to enroll in our study. Nine participants were excluded from the analysis because of unconfirmed age (one child) or ZIKV testing results (seven children), and a preexisting neurological condition, focal seizures (one child). There was a delay between enrollment into the transmission study and subsequent enrollment in our follow-up study: the first assessment (baseline visit) occurred 2–217 days (median 32; interquartile range (IQR) 16–146 days) after enrollment in the transmission study; the last assessment occurred 220–761 days (median 408; IQR 378–561 days) after enrollment in the follow-up study. All 62 children for whom baseline visit data were collected participated in a follow-up visit about 6 months later (6-month visit) and 60 participated in a second follow-up visit (12-month visit). Laboratory results confirmed that 40 children had ZIKV infection and 22 had not. No significant demographic differences were seen between the ZIKV-infected and -uninfected groups (Table 2). In children aged 13 years and older, no drug use was reported and no children were at risk of alcohol abuse (data not shown).
TABLE 2.

Baseline characteristics of the participants, by Zika virus infection, León, Nicaragua

Characteristic

ZIKV (n = 40)

No ZIKV (n = 22)

Total (n = 62)

p-value[a]

n (%)

n (%)

n (%)

Age group at baseline (years)

 

 

 

 

    2–5

5 (12)

3 (14)

8 (13)

0.4697

    6–12

16 (40)

12 (54)

28 (45)

 

    13–17

19 (48)

7 (32)

26 (42)

 

Sex

 

 

 

 

    Male

18 (45)

10 (46)

28 (45)

0.9725

    Female

22 (55)

12 (54)

34 (55)

 

Poverty[b]

 

 

 

 

    Not poor

11 (28)

8 (36)

19 (31)

0.2173

    Poor

18 (45)

5 (23)

23 (37)

 

    Extremely poor

11 (28)

9 (41)

20 (32)

 

Family history of neurological disorder

 

 

 

 

    Yes

8 (20)

3 (14)

11 (18)

0.5303

    No

32 (80)

19 (86)

51 (82)

 

ZIKV = had Zika virus infection; no ZIKV = did not have Zika virus infection.

Chi-squared test.

Poverty definitions. Not poor if there are no problems with sanitary services, home conditions, home density, education, or economic problems; poor if one of these problems exists; extremely poor if two or more of these problems exist. Sanitary services problem: if water source is a community well, river, bottled water or gifted, OR there is no toilet, OR there is no electricity. Home conditions problem: if walls are constructed from wood, palm leaves, or cardboard/plastic/metal, OR there is a dirt floor, OR the roof is constructed from cardboard/plastic or palm leaves. Home density problem: if the number of people living in the home divided by the number of rooms used for sleeping is > 2.5. Education problem: if one or more children age 7–14 years living in the home does not attend school. Economic problem: if number of dependents living in home plus the number of unemployed persons (age 15-65 years) living in the home divided by the number of employed persons living in the home is < 2 OR there are one or more dependents living in the home OR one or more unemployed persons (age 15–65 years) living in the home AND no one living in the home is employed.

Characteristic ZIKV (n = 40) No ZIKV (n = 22) Total (n = 62) p-value[a] n (%) n (%) n (%) Age group at baseline (years) 2–5 5 (12) 3 (14) 8 (13) 0.4697 6–12 16 (40) 12 (54) 28 (45) 13–17 19 (48) 7 (32) 26 (42) Sex Male 18 (45) 10 (46) 28 (45) 0.9725 Female 22 (55) 12 (54) 34 (55) Poverty[b] Not poor 11 (28) 8 (36) 19 (31) 0.2173 Poor 18 (45) 5 (23) 23 (37) Extremely poor 11 (28) 9 (41) 20 (32) Family history of neurological disorder Yes 8 (20) 3 (14) 11 (18) 0.5303 No 32 (80) 19 (86) 51 (82) ZIKV = had Zika virus infection; no ZIKV = did not have Zika virus infection. Chi-squared test. Poverty definitions. Not poor if there are no problems with sanitary services, home conditions, home density, education, or economic problems; poor if one of these problems exists; extremely poor if two or more of these problems exist. Sanitary services problem: if water source is a community well, river, bottled water or gifted, OR there is no toilet, OR there is no electricity. Home conditions problem: if walls are constructed from wood, palm leaves, or cardboard/plastic/metal, OR there is a dirt floor, OR the roof is constructed from cardboard/plastic or palm leaves. Home density problem: if the number of people living in the home divided by the number of rooms used for sleeping is > 2.5. Education problem: if one or more children age 7–14 years living in the home does not attend school. Economic problem: if number of dependents living in home plus the number of unemployed persons (age 15-65 years) living in the home divided by the number of employed persons living in the home is < 2 OR there are one or more dependents living in the home OR one or more unemployed persons (age 15–65 years) living in the home AND no one living in the home is employed.

Neurological observations

Twenty ZIKV-infected children had their baseline visit within 60 days of enrollment in the transmission study. These children displayed a range of neurological symptoms, some persisting for 6 to 12 months after infection, although no consistent pattern of symptoms was observed. Some of the more severe or persistent problems experienced included: a 13-year-old male with persistent memory difficulty and cognitive slowness accompanied by sensory loss; a 7-year-old female exhibiting abnormal awareness at all three visits; a 13-year-old female with severe headache and memory difficulty at two consecutive visits; a 16-year-old male with persistent headache and sensory loss; and a 13-year-old male with moderate sensory loss at baseline and persistent self-reported forgetfulness and cognitive slowness. Full descriptive information about the neurological outcomes of these children is available upon request to the authors. When comparing the ZIKV-infected and -uninfected cohort, hallmark signs of neurological problems (e.g., fatigue, memory loss/confusion, difficulty concentrating/reduced speed of thought, and sensory problems) were self-reported by children or their parents in both groups (Table 3). At baseline, the most commonly reported symptoms were headache, lethargy, myalgia, and arthralgia; these symptoms were more frequently reported in ZIKV-infected children at the baseline and 6-month visits.
TABLE 3.

Self-reported symptoms (by the children or their parents) experienced by Zika virus infection at baseline, 6-month, and 12-month visits, León, Nicaragua

Self-reported symptoms that started after Zika virus test

Baseline

6-month visit

12-month visit

ZIKV (n = 40)

No ZIKV (n = 22)

ZIKV (n = 40)

No ZIKV (n = 22)

ZIKV (n = 40)

No ZIKV (n = 20)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Fatigue

5 (13)

2 (9)

7 (18)

3 (14)

5 (13)

3 (15)

    Mild fatigue, limits most demanding activities

2

0

4

3

3

1

    Moderate or severe fatigue

3

2

3

0

2

2

Memory loss/confusion

5 (13)

3 (14)

4 (10)

0 (0)

5 (13)

5 (25)

    Mildly more forgetful than usual

2

1

2

0

4

3

    Definite memory difficulty or confused/persistently confused

3

2

2

0

1

2

Difficulty concentrating/reduced speed of thought

5 (13)

2 (9)

4 (10)

1 (5)

5 (13)

5 (25)

    Needs longer time to accomplish normal tasks, but able to manage nearly all of daily affairs

4

0

4

1

4

5

    Loses track of conversations or tasks, or marked/severe slowing or loss of train of thought

1

2

0

0

1

0

Mildly impaired vision, retains normal activities

1 (3)

0 (0)

2 (5)

0 (0)

0 (0)

0 (0)

Mildly impaired hearing, retains normal activities

1 (3)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Reduced interest in social activities

3 (8)

1 (5)

0 (0)

1 (5)

0 (0)

2 (10)

    Mild limitation because of reduced interest

3

1

0

1

0

1

    Moderate or severe reduction in social activities because of lack of interest or initiative

0

0

0

0

0

1

Sensory problems

7 (18)

3 (14)

9 (23)

3 (14)

3 (8)

3 (15)

    Mild sensory loss or paresthesia – intermittent or nonintrusive

4

3

8

3

2

3

    Moderate or severe sensory loss or paresthesia always present

3

0

1

0

1

0

Headaches within the past 4 weeks

12 (30)

11 (50)

11 (28)

8 (36)

15 (38)

4 (20)

    Mild, occasional (about one a week)

4

6

7

6

6

2

    Moderate, interferes with activities or sleep (several a week)

4

2

3

2

6

1

    Severe, debilitating (daily or almost every day)

4

3

1

0

3

1

Self-reported neurological symptoms in the past 30 days

 

 

 

 

 

 

 

    Any

16 (40)

2 (9)

11 (28)

3 (14)

2 (5)

2 (10)

    Lethargy (extreme tiredness)

12 (30)

1 (5)

9 (23)

2 (9)

0 (0)

1 (5)

    Myalgia (muscle pain)

7 (18)

1 (5)

4 (10)

0 (0)

1 (3)

0 (0)

    Arthralgia (joint pain)

5 (13)

2 (9)

3 (8)

0 (0)

0 (0)

1 (5)

    Weakness in arms or legs

4 (10)

0 (0)

4 (10)

1 (5)

1 (3)

0 (0)

ZIKV = had Zika virus infection; no ZIKV = did not have Zika virus infection.

Clinically observed abnormal awareness and speech/language abnormalities were observed in both groups and varied over time (data not shown). At baseline, a small percentage of children with ZIKV infection had an abnormal finger-to-nose test (13%), cold touch response (13%), and vibration response (15%) versus 0% in the uninfected group (data not shown). No seizures, paralysis, or walking problems were reported (data not shown). At all time points, ZIKV-infected children were more likely to experience more than two strength or reflex problems compared to children who were not exposed – baseline: 15% versus 0%; 6-month: 7.5% versus 0%; 12-month: 10% versus 4.5%. Detailed data are available upon request.

Neuropsychological and behavioral findings

Descriptive statistics for the cognitive, behavior, anxiety, and depression assessments are shown in Table 4. Low scores on the neurocognitive tests were common in both groups. The 95% CIs of the difference in the at-risk prevalence were wide, with the CIs crossing zero for most domains (Figure 1). The proportion of children with an at-risk cognitive efficiency composite score was significantly greater in the infected group than the uninfected group at 6 months, but this difference was smaller at the 12-month visit. This observed difference in the cognitive efficiency composite score is driven mainly by the fact that 100% of infected children at 6 months had an at-risk score for the visual matching subtest (data not shown). At the 6-month visit, a larger proportion of children in the uninfected group had caregiver-reported behavior problems as assessed by the Child Behavior Checklist, compared to the infected group. This pattern was also seen at the 12-month visit, although CIs were wide due to fewer participant responses. We did not see any difference in depression or anxiety by infection. In general, the small sample sizes precluded drawing any solid conclusions about differences in neuropsychological deficits and behavioral problems between ZIKV-infected and -uninfected children.
TABLE 4.

Neuropsychological and behavioral functioning at 6-month and 12-month visits by Zika virus infection, León, Nicaragua

Test

Test output

6-month visit

12-month visit

ZIKV

No ZIKV

ZIKV

No ZIKV

n

Mean score (SD)

n

Mean score (SD)

n

Mean score (SD)

n

Mean score (SD)

Test of Nonverbal Intelligence, fourth edition

Non-verbal IQ

16

85.3 (11.1)

12

87.9 (10.9)

32

89.4 (12.8)

14

88.1 (10.7)

Woodcock–Muñoz III Cognitive Battery

 

 

 

 

 

 

 

 

 

    Verbal comprehension

Vocabulary and word usage

18

90.9 (12.2)

14

89.6 (14.0)

34

92.7 (16.6)

16

86.5 (20.9)

    Visual–auditory learning

Multimodal learning

17

93.9 (11.6)

14

88.6 (20.2)

29

95.8 (11.0)

14

89.6 (18.0)

    Spatial relations

Visual-spatial

16

91.2 (7.8)

14

86.0 (21.6)

29

88.1 (15.6)

14

88.6 (22.1)

    Concept formation

Problem solving

17

87.9 (15.1)

13

87.8 (16.1)

29

86.2 (12.8)

13

93.9 (16.5)

    Visual matching

Processing speed

18

55.7 (15.7)

14

73.6 (20.2)

33

61.6 (16.7)

16

67.3 (20.1)

    Numbers reversed

Verbal working memory

17

91.0 (11.6)

14

98.0 (22.7)

29

91.7 (10.8)

14

97.6 (23.5)

    Incomplete words

Phonological processing

18

109.6 (18.8)

14

114.6 (25.6)

33

111.1 (20.2)

15

112.1 (24.1)

    Auditory working memory

Verbal working memory

17

97.1 (16.5)

14

102.8 (12.3)

29

100.4 (11.9)

14

99.1 (12.0)

Woodcock–Muñoz III Cognitive Battery composite scores

 

 

 

 

 

 

 

 

 

    Cognitive efficiency

Visual matching and numbers reversed

17

69.6 (11.6)

13

82.4 (16.4)

29

73.0 (11.7)

13

77.2 (17.4)

    Working memory

Numbers reversed and auditory working memory

17

91.9 (12.7)

14

99.7 (20.8)

29

94.2 (9.9)

14

97.5 (21.2)

Child Behavior Checklist (parent report)

 

 

 

 

 

 

 

 

 

    Internalizing problems

Mood disturbance, including anxiety, depression, and social withdrawal

35

57.4 (12.7)

20

57.4 (12.6)

13

50.1 (11.5)

7

65.3 (19.1)

    Externalizing problems

Conflict with others and violation of social norms

35

54.1 (11.3)

20

54.7 (13.9)

13

52.1 (8.9)

7

65.0 (13.7)

    Total problems

Combination of internalizing and externalizing

35

56.6 (11.7)

20

57.4 (13.8)

13

52.2 (9.1)

7

66.6 (16.5)

Child Depression Inventory (age 7–12 years)

Symptoms of depression

15

7.7 (5.1)

10

9.8 (4.2)

13

9.7 (6.2)

10

9.3 (8.7)

Beck Depression Inventory (age 13–18 years)

Symptoms of depression

24

6.4 (10.1)

9

7.4 (6.9)

26

6.0 (7.0)

8

5.0 (9.4)

Spence Anxiety Scale (age 8–12 years)

Anxiety disorder symptoms

14

26.1 (20.3)

9

27.6 (14.7)

13

20.7 (20.6)

10

32.2 (23.8)

Beck Anxiety Inventory (age 13–18 years)

Anxiety severity and level

20

10.8 (9.2)

8

9.3 (10.2)

22

8.6 (7.4)

7

5.9 (8.4)

SD, standard deviation; IQ, intelligence quotient.

ZIKV= had Zika virus infection; no ZIKV = did not have Zika virus infection.

Test of Nonverbal Intelligence, fourth edition: higher scores indicate higher intellectual functioning.

Woodcock-Muñoz III Cognitive Battery subtests/composites: higher scores indicate higher achievement.

Child Behavior Checklist: higher scores indicate greater degree of behavioral and emotional problems.

Child Depression Inventory: higher scores indicate a more depressive state; scores ≥ 19 indicate likely depression.

Beck Depression Inventory: higher scores indicate a more depressive state; scores ≥ 31 indicate likely depression.

Spence Child Anxiety Scale: higher scores indicate more anxiety; scores ≥ 40 indicate elevated total anxiety for males aged 8–11 years; scores ≥ 50 indicate elevated total anxiety for females aged 8–11 years; scores ≥ 33 indicate elevated total anxiety for males aged 12–15 years; scores ≥ 39 indicate elevated total anxiety for females aged 12–15 years.

Beck Anxiety Inventory: higher scores indicate more anxiety; scores ≥ 36 indicate elevated total anxiety.

FIGURE 1.

Difference in at-risk prevalence and 95% confidence interval of neuropsychological problems at 6-month and 12-month visits between children with Zika virus infection and uninfected children, León, Nicaragua

DISCUSSION

We conducted an evaluation of neurological, neurocognitive, and neuropsychiatric outcomes following ZIKV infection in children and included children without ZIKV infection for comparison. Although our study is small, it builds on emergent findings suggesting possible neurological involvement of ZIKV in children postnatally exposed to the virus, with long-term impacts in some cases. Neurocognitive and behavioral problems, some reflecting clear deficits, were common in both groups, while anxiety and depression were observed infrequently in both groups. Although case reports have described central nervous system and peripheral nervous system sequelae following ZIKV infection, characterization of neurological symptoms of acquired ZIKV infection among children is limited (7, 27). The largest pediatric case series to date included 18 756 suspected pediatric cases of ZIKV infection reported to Colombia’s national surveillance system. Ninety-six instances of neurological manifestations secondary to ZIKV were reported, including peripheral nervous system disorders and degenerative and inflammatory diseases of the central nervous system (9). However, only 25 of the 96 suspected cases were tested for ZIKV, and only 12 of those had laboratory evidence of ZIKV. In a recent systematic review, six of 34 pediatric ZIKV case reports included descriptions of neurological complications, including acute myelitis, encephalitis, peripheral neuropathy, left middle cerebral artery infarct with right hemiparesis, seizures and diffuse neurological manifestations, and Alice in Wonderland syndrome (27). Self-reported symptoms that started after Zika virus test Baseline 6-month visit 12-month visit ZIKV (n = 40) No ZIKV (n = 22) ZIKV (n = 40) No ZIKV (n = 22) ZIKV (n = 40) No ZIKV (n = 20) n (%) n (%) n (%) n (%) n (%) n (%) Fatigue 5 (13) 2 (9) 7 (18) 3 (14) 5 (13) 3 (15) Mild fatigue, limits most demanding activities 2 0 4 3 3 1 Moderate or severe fatigue 3 2 3 0 2 2 Memory loss/confusion 5 (13) 3 (14) 4 (10) 0 (0) 5 (13) 5 (25) Mildly more forgetful than usual 2 1 2 0 4 3 Definite memory difficulty or confused/persistently confused 3 2 2 0 1 2 Difficulty concentrating/reduced speed of thought 5 (13) 2 (9) 4 (10) 1 (5) 5 (13) 5 (25) Needs longer time to accomplish normal tasks, but able to manage nearly all of daily affairs 4 0 4 1 4 5 Loses track of conversations or tasks, or marked/severe slowing or loss of train of thought 1 2 0 0 1 0 Mildly impaired vision, retains normal activities 1 (3) 0 (0) 2 (5) 0 (0) 0 (0) 0 (0) Mildly impaired hearing, retains normal activities 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Reduced interest in social activities 3 (8) 1 (5) 0 (0) 1 (5) 0 (0) 2 (10) Mild limitation because of reduced interest 3 1 0 1 0 1 Moderate or severe reduction in social activities because of lack of interest or initiative 0 0 0 0 0 1 Sensory problems 7 (18) 3 (14) 9 (23) 3 (14) 3 (8) 3 (15) Mild sensory loss or paresthesia – intermittent or nonintrusive 4 3 8 3 2 3 Moderate or severe sensory loss or paresthesia always present 3 0 1 0 1 0 Headaches within the past 4 weeks 12 (30) 11 (50) 11 (28) 8 (36) 15 (38) 4 (20) Mild, occasional (about one a week) 4 6 7 6 6 2 Moderate, interferes with activities or sleep (several a week) 4 2 3 2 6 1 Severe, debilitating (daily or almost every day) 4 3 1 0 3 1 Self-reported neurological symptoms in the past 30 days Any 16 (40) 2 (9) 11 (28) 3 (14) 2 (5) 2 (10) Lethargy (extreme tiredness) 12 (30) 1 (5) 9 (23) 2 (9) 0 (0) 1 (5) Myalgia (muscle pain) 7 (18) 1 (5) 4 (10) 0 (0) 1 (3) 0 (0) Arthralgia (joint pain) 5 (13) 2 (9) 3 (8) 0 (0) 0 (0) 1 (5) Weakness in arms or legs 4 (10) 0 (0) 4 (10) 1 (5) 1 (3) 0 (0) ZIKV = had Zika virus infection; no ZIKV = did not have Zika virus infection. The most comprehensive study of neurological manifestations associated with ZIKV infection to date identified 87 laboratory-confirmed ZIKV virus patients during the 2016 outbreak in the French West Indies with diverse clinical manifestations in the central nervous system and peripheral nervous system, and associated findings in magnetic resonance imaging (10). This study only included six children, with diagnoses of Guillain–Barré syndrome, meningoencephalitis, stroke, and myeloradiculitis and neurological symptoms including headaches, myalgia, ataxia, bilateral motor weakness, areflexia, sensory problems, and seizures. Although our study physicians conducted a detailed assessment of neurological signs and symptoms, diagnosis of neurological conditions (e.g., myelitis and encephalitis) was beyond the scope of our study. Similar to Lannuzel et al. (10), our study observed headache, myalgia, ataxia, strength and reflex abnormalities, and sensory problems, but most of these symptoms were reported by both infected and uninfected children. Test Test output 6-month visit 12-month visit ZIKV No ZIKV ZIKV No ZIKV n Mean score (SD) n Mean score (SD) n Mean score (SD) n Mean score (SD) Test of Nonverbal Intelligence, fourth edition Non-verbal IQ 16 85.3 (11.1) 12 87.9 (10.9) 32 89.4 (12.8) 14 88.1 (10.7) Woodcock–Muñoz III Cognitive Battery Verbal comprehension Vocabulary and word usage 18 90.9 (12.2) 14 89.6 (14.0) 34 92.7 (16.6) 16 86.5 (20.9) Visual–auditory learning Multimodal learning 17 93.9 (11.6) 14 88.6 (20.2) 29 95.8 (11.0) 14 89.6 (18.0) Spatial relations Visual-spatial 16 91.2 (7.8) 14 86.0 (21.6) 29 88.1 (15.6) 14 88.6 (22.1) Concept formation Problem solving 17 87.9 (15.1) 13 87.8 (16.1) 29 86.2 (12.8) 13 93.9 (16.5) Visual matching Processing speed 18 55.7 (15.7) 14 73.6 (20.2) 33 61.6 (16.7) 16 67.3 (20.1) Numbers reversed Verbal working memory 17 91.0 (11.6) 14 98.0 (22.7) 29 91.7 (10.8) 14 97.6 (23.5) Incomplete words Phonological processing 18 109.6 (18.8) 14 114.6 (25.6) 33 111.1 (20.2) 15 112.1 (24.1) Auditory working memory Verbal working memory 17 97.1 (16.5) 14 102.8 (12.3) 29 100.4 (11.9) 14 99.1 (12.0) Woodcock–Muñoz III Cognitive Battery composite scores Cognitive efficiency Visual matching and numbers reversed 17 69.6 (11.6) 13 82.4 (16.4) 29 73.0 (11.7) 13 77.2 (17.4) Working memory Numbers reversed and auditory working memory 17 91.9 (12.7) 14 99.7 (20.8) 29 94.2 (9.9) 14 97.5 (21.2) Child Behavior Checklist (parent report) Internalizing problems Mood disturbance, including anxiety, depression, and social withdrawal 35 57.4 (12.7) 20 57.4 (12.6) 13 50.1 (11.5) 7 65.3 (19.1) Externalizing problems Conflict with others and violation of social norms 35 54.1 (11.3) 20 54.7 (13.9) 13 52.1 (8.9) 7 65.0 (13.7) Total problems Combination of internalizing and externalizing 35 56.6 (11.7) 20 57.4 (13.8) 13 52.2 (9.1) 7 66.6 (16.5) Child Depression Inventory (age 7–12 years) Symptoms of depression 15 7.7 (5.1) 10 9.8 (4.2) 13 9.7 (6.2) 10 9.3 (8.7) Beck Depression Inventory (age 13–18 years) Symptoms of depression 24 6.4 (10.1) 9 7.4 (6.9) 26 6.0 (7.0) 8 5.0 (9.4) Spence Anxiety Scale (age 8–12 years) Anxiety disorder symptoms 14 26.1 (20.3) 9 27.6 (14.7) 13 20.7 (20.6) 10 32.2 (23.8) Beck Anxiety Inventory (age 13–18 years) Anxiety severity and level 20 10.8 (9.2) 8 9.3 (10.2) 22 8.6 (7.4) 7 5.9 (8.4) SD, standard deviation; IQ, intelligence quotient. ZIKV= had Zika virus infection; no ZIKV = did not have Zika virus infection. Test of Nonverbal Intelligence, fourth edition: higher scores indicate higher intellectual functioning. Woodcock-Muñoz III Cognitive Battery subtests/composites: higher scores indicate higher achievement. Child Behavior Checklist: higher scores indicate greater degree of behavioral and emotional problems. Child Depression Inventory: higher scores indicate a more depressive state; scores ≥ 19 indicate likely depression. Beck Depression Inventory: higher scores indicate a more depressive state; scores ≥ 31 indicate likely depression. Spence Child Anxiety Scale: higher scores indicate more anxiety; scores ≥ 40 indicate elevated total anxiety for males aged 8–11 years; scores ≥ 50 indicate elevated total anxiety for females aged 8–11 years; scores ≥ 33 indicate elevated total anxiety for males aged 12–15 years; scores ≥ 39 indicate elevated total anxiety for females aged 12–15 years. Beck Anxiety Inventory: higher scores indicate more anxiety; scores ≥ 36 indicate elevated total anxiety. It is also important to understand the longer-term consequences of acquired ZIKV infection. A study by Salgado et al. (8) included 20 pediatric patients with suspected encephalitis, six of whom were confirmed to have ZIKV infection. Compared to children with other causes of encephalitis, children with ZIKV-associated encephalitis experienced shorter duration of hospitalization, with a maximum recovery time of 10 days. No sequelae were found during clinical follow-up of unknown duration (8). Of the six children followed for over a year in the French West Indies study, only the one child with myeloradiculitis had persistent neurological problems (10). In our study, the reflex problems and limb weakness observed at baseline mostly resolved over time, although for several children reflex issues were reported at all visits. Other symptoms reported at multiple visits were headache and fatigue. Our study found an array of neurocognitive concerns. To our knowledge, the only other study to include any measure of neurocognition among children infected with ZIKV postnatally was conducted in Chiapas, Mexico using the Montreal Cognitive Assessment (13). Investigators saw no improvement in cognitive scores between 0 to 7 days but did see improved cognitive scores from 7 to 28 days, likely related to better overall health and ability to function. No significant changes in function overall or in any cognitive subdomains were observed long term, between 28 and 108 days postinfection (13). In cognitive functioning assessments, we observed a higher prevalence of scores in the at-risk range among children infected with ZIKV compared to uninfected children on the visual matching subtest, which is a measure of processing speed. This finding may be explained by the damaging effects of ZIKV on myelination processes and axonal functioning in the white matter structures of humans, areas of the brain thought to be foundational to processing speed across the lifespan (28–30). Although behavioral problems have been reported in infants and toddlers exposed to ZIKV in utero, to our knowledge, no behavioral assessments of children with postnatal ZIKV infection have been conducted. The only study contributing evidence to the hypothesized link between postnatal ZIKV infection and behavioral outcomes was conducted among six rhesus macaques infected with ZIKV postnatally (31). Neuroimaging revealed virus neuroinvasion, with a pattern of astrogliosis also seen in in utero ZIKV infection in humans and mice (32, 33). Magnetic resonance imaging conducted at 3 and 6 months of age revealed enlargement of lateral ventricles and blunted increases in hippocampal volume. Altered functional connectivity between brain regions that regulate emotional behavior and arousal functions was also seen (e.g., between amygdala and hippocampus) and corresponded with observed abnormal emotional behavior during intruder threat testing. In our study, the prevalence of behavioral issues measured by the Child Behavior Checklist was not significantly greater in the ZIKV-infected group. Longitudinal follow-up of the aforementioned rhesus macaques observed persistent structural and functional changes of the hippocampus at 12 months of age associated with memory deficits in ZIKV-infected macaques compared to controls (34). We did not see significant differences in memory between infection groups in our small study. The high prevalence of at-risk scores for cognitive and behavioral issues may be the result of high rates of poverty in León, a general lack of access to remedial resources for learning deficits or disabilities, and the environment of violent civil and social unrest occurring during the course of study follow-up (35, 36). About 15–20% of children aged 7–12 years had elevated anxiety levels, a finding that deserves further attention, particularly with respect to studying the impact of anxiety on cognition and behavior. Our study had some limitations. Although our goal was to include a group of children unaffected by ZIKV against which to compare outcomes in the ZIKV-infected group, the small number of children recruited precluded statistical comparisons and stratification by age. Furthermore, because children in the study only had mild ZIKV infections, our study was underpowered to detect significant differences in neurological and neuropsychological sequelae between groups. We also lacked neurocognitive and neuropsychiatric data on the children before infection to help determine whether observed deficits existed before the Zika epidemic. Some neurological symptoms are difficult to assess in small children; we may therefore have missed important neurological sequelae, but the inclusion of both parent-reported observations and a clinician evaluation attempted to reduce the effect of this potential limitation. The strength of this study is that we were able to implement for research purposes a standardized clinical neurological evaluation and a standardized neurocognitive and neuropsychiatric assessment battery in this resource-constrained Spanish-speaking population. We selected measures that minimized the potential influence of cultural and language factors on the standardized scores. For example, we used the Woodcock Muñoz III Cognitive Battery, a Spanish version of the Woodcock Johnson III. Norms were calibrated based on validation testing among Spanish-speaking children within and outside of the United States, including from Central America (19). The Test of Nonverbal Intelligence 4 uses shapes that are not culturally specific and avoids any need for verbal communication. The Child Behavior Checklist has been used in previous behavior studies in Nicaragua, and we selected the Children’s Depression Inventory, Beck Depression Inventory, and Spence Child Anxiety Scale depression and anxiety instruments for this study because they were already in use in the family clinic at the study site (37, 38). The feasibility of implementing such a comprehensive testing battery is particularly important in the context of Nicaragua, where a shortage of medical specialists including neurologists has been further worsened by the recent political crisis (39, 40). The fact that general physicians and psychologists can be successfully trained to implement pediatric neurological, neurocognitive, and neuropsychiatric assessments is encouraging for supporting research in underserved populations in Nicaragua.

Conclusion

Although we observed neurological symptoms and neurocognitive problems among children exposed to ZIKV, these outcomes were not significantly more common in these children compared to uninfected individuals. While we developed a successful protocol for evaluating neurocognitive and neurobehavioral sequelae of ZIKV, larger studies are needed to definitively investigate this relationship to allow for stratification by age and adjustment for factors affecting neurocognition, e.g., mood and sleep disorders, child’s home learning environment, history of other neuroinvasive infections such as dengue and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a detailed family history of neurological and neurocognitive problems. Nevertheless, our study protocol can inform larger studies of neurological complications of ZIKV in the still-developing brains of children, particularly in resource-constrained settings where sequelae may be obscured by the effects of other sociopolitical and health-system challenges.

Disclaimer.

Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the Revista Panamericana de Salud Pública / Pan American Journal of Public Health and/or those of the Pan American Health Organization.
  32 in total

Review 1.  The Child Behavior Checklist and related forms for assessing behavioral/emotional problems and competencies.

Authors:  T M Achenbach; T M Ruffle
Journal:  Pediatr Rev       Date:  2000-08

2.  Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study.

Authors:  Raquel Burger-Calderon; Fausto Bustos Carrillo; Lionel Gresh; Sergio Ojeda; Nery Sanchez; Miguel Plazaola; Leah Katzelnick; Brenda Lopez Mercado; Jairo Carey Monterrey; Douglas Elizondo; Sonia Arguello; Andrea Nuñez; Aubree Gordon; Angel Balmaseda; Guillermina Kuan; Eva Harris
Journal:  Lancet Infect Dis       Date:  2019-12-20       Impact factor: 25.071

3.  The politicised and crumbling Nicaraguan health system.

Authors:  Elena Vargas-Palacios; Ricardo Pineda; Edén Galán-Rodas
Journal:  Lancet       Date:  2018 Dec 22 -Jan 4 2019       Impact factor: 79.321

4.  The REDCap consortium: Building an international community of software platform partners.

Authors:  Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda
Journal:  J Biomed Inform       Date:  2019-05-09       Impact factor: 6.317

5.  Postnatal Zika virus infection is associated with persistent abnormalities in brain structure, function, and behavior in infant macaques.

Authors:  Maud Mavigner; Jessica Raper; Zsofia Kovacs-Balint; Sanjeev Gumber; Justin T O'Neal; Siddhartha K Bhaumik; Xiaodong Zhang; Jakob Habib; Cameron Mattingly; Circe E McDonald; Victoria Avanzato; Mark W Burke; Diogo M Magnani; Varian K Bailey; David I Watkins; Thomas H Vanderford; Damien Fair; Eric Earl; Eric Feczko; Martin Styner; Sherrie M Jean; Joyce K Cohen; Guido Silvestri; R Paul Johnson; David H O'Connor; Jens Wrammert; Mehul S Suthar; Mar M Sanchez; Maria C Alvarado; Ann Chahroudi
Journal:  Sci Transl Med       Date:  2018-04-04       Impact factor: 17.956

6.  High maternal cortisol levels during pregnancy are associated with more psychiatric symptoms in offspring at age of nine - A prospective study from Nicaragua.

Authors:  J Isaksson; F Lindblad; E Valladares; U Högberg
Journal:  J Psychiatr Res       Date:  2015-09-30       Impact factor: 4.791

7.  Clinical, laboratory and immune aspects of Zika virus-associated encephalitis in children.

Authors:  Doris M Salgado; Rocío Vega; Jairo Antonio Rodríguez; Ángela Niño; Rocío Rodríguez; Ángela Ortiz; Isabel DeLaura; Irene Bosch; Carlos F Narváez
Journal:  Int J Infect Dis       Date:  2019-10-31       Impact factor: 3.623

8.  The Relationship between Processing Speed and Regional White Matter Volume in Healthy Young People.

Authors:  Daniele Magistro; Hikaru Takeuchi; Keyvan Kashkouli Nejad; Yasuyuki Taki; Atsushi Sekiguchi; Rui Nouchi; Yuka Kotozaki; Seishu Nakagawa; Carlos Makoto Miyauchi; Kunio Iizuka; Ryoichi Yokoyama; Takamitsu Shinada; Yuki Yamamoto; Sugiko Hanawa; Tsuyoshi Araki; Hiroshi Hashizume; Yuko Sassa; Ryuta Kawashima
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

9.  Zika Virus Infection Leads to Demyelination and Axonal Injury in Mature CNS Cultures.

Authors:  Verena Schultz; Stephanie L Cumberworth; Quan Gu; Natasha Johnson; Claire L Donald; George A McCanney; Jennifer A Barrie; Ana Da Silva Filipe; Christopher Linington; Hugh J Willison; Julia M Edgar; Susan C Barnett; Alain Kohl
Journal:  Viruses       Date:  2021-01-11       Impact factor: 5.048

Review 10.  Autoimmune Neurological Conditions Associated With Zika Virus Infection.

Authors:  Yeny Acosta-Ampudia; Diana M Monsalve; Luis F Castillo-Medina; Yhojan Rodríguez; Yovana Pacheco; Susan Halstead; Hugh J Willison; Juan-Manuel Anaya; Carolina Ramírez-Santana
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.